230 related articles for article (PubMed ID: 24723566)
1. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
Figarella-Branger D; Mokhtari K; Dehais C; Jouvet A; Uro-Coste E; Colin C; Carpentier C; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A;
Neuro Oncol; 2014 Sep; 16(9):1244-54. PubMed ID: 24723566
[TBL] [Abstract][Full Text] [Related]
2. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
Reyes-Botero G; Dehais C; Idbaih A; Martin-Duverneuil N; Lahutte M; Carpentier C; Letouzé E; Chinot O; Loiseau H; Honnorat J; Ramirez C; Moyal E; Figarella-Branger D; Ducray F;
Neuro Oncol; 2014 May; 16(5):662-70. PubMed ID: 24353325
[TBL] [Abstract][Full Text] [Related]
3. Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas.
Figarella-Branger D; Mokhtari K; Dehais C; Carpentier C; Colin C; Jouvet A; Uro-Coste E; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A; Delattre JY;
Neuro Oncol; 2016 Jun; 18(6):888-90. PubMed ID: 27175000
[No Abstract] [Full Text] [Related]
4. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
5. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
6. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
[TBL] [Abstract][Full Text] [Related]
7. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
8. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.
Pouget C; Hergalant S; Lardenois E; Lacomme S; Houlgatte R; Carpentier C; Dehais C; Rech F; Taillandier L; Sanson M; Appay R; Colin C; Figarella-Branger D; Battaglia-Hsu SF; Gauchotte G
Brain Pathol; 2020 May; 30(3):465-478. PubMed ID: 31561286
[TBL] [Abstract][Full Text] [Related]
10. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
[TBL] [Abstract][Full Text] [Related]
11. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
[TBL] [Abstract][Full Text] [Related]
12. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
13. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.
Chen H; Thomas C; Munoz FA; Alexandrescu S; Horbinski CM; Olar A; McGuone D; Camelo-Piragua S; Wang L; Pentsova E; Phillips J; Aldape K; Chen W; Iafrate AJ; Chi AS; Zagzag D; Golfinos JG; Placantonakis DG; Rosenblum M; Ohman-Strickland P; Hameed M; Snuderl M
Neuro Oncol; 2019 Sep; 21(9):1164-1174. PubMed ID: 31140557
[TBL] [Abstract][Full Text] [Related]
14. Recurrent oligodendroglioma with changed 1p/19q status.
Barresi V; Mafficini A; Calicchia M; Piredda ML; Musumeci A; Ghimenton C; Scarpa A
Neuropathology; 2022 Apr; 42(2):160-166. PubMed ID: 35144313
[TBL] [Abstract][Full Text] [Related]
15. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
Sathornsumetee S; Cheunsuchon P; Sangruchi T
World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
[TBL] [Abstract][Full Text] [Related]
16. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
17. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
Snuderl M; Eichler AF; Ligon KL; Vu QU; Silver M; Betensky RA; Ligon AH; Wen PY; Louis DN; Iafrate AJ
Clin Cancer Res; 2009 Oct; 15(20):6430-7. PubMed ID: 19808867
[TBL] [Abstract][Full Text] [Related]
18. Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.
Rajmohan KS; Sugur HS; Shwetha SD; Pandey P; Arivazhagan A; Santosh V
Neurol India; 2020; 68(4):832-837. PubMed ID: 32859823
[TBL] [Abstract][Full Text] [Related]
19. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
20. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
